TSI Health Sciences gets Australian TGA approval

By staff reporter

- Last updated on GMT

Related tags Ginkgo Ginkgo biloba

TSI Health Sciences has secured approval from the Australian
Therapeutic Goods Administration (TGA) for manufacturing
chondroitin sulfate sodium, thereby opening up another avenue of
business for the Montana-headquartered company.

TSI last year completed its evolution from ingredients sourcing and distribution to production and now wholly owns the manufacturing operations of Jiangyin TSI Pharmaceutical in Jiangsu, China. Since the Australian TGA has verified and approved its TSI-Yangzhou Natural Products Company for glucosamine production, the company can now add Australia to the list of countries it can market to. It is also taking the TGA approval as a pat-on-the-back of sorts. "The TGA process is among the most stringent in the world,"​ said TSI president Larry Kolb. "It means we have absolute and total control of our manufacturing processes."​ The company has positioned itself as a supplier to high-end consumer branded supplements. TSI's branded ingredients include Peak ATP(adenosine triphosphate) for improvement in circulation, energy and overall well-being. It also offers Promilin fenugreek extract, PureFlex chondriotin sulphate and glucosamine, Ostivone ipriflavone, and Ginkgo 24/6/5 extract of ginko biloba. TSI last year told NutraIngredients-USA.com that it had a number of new ingredients in the pipeline. The company is particularly keen on opportunities in the sports nutrition and antioxidant channels.

Related news

Show more

Related products

show more

Stay one step ahead in the collagen market

Stay one step ahead in the collagen market

Content provided by Bioiberica | 26-Feb-2024 | White Paper

It's no secret that interest in collagen is at an all-time high – especially for joint health. This presents a real opportunity for manufacturers...

Related suppliers

Follow us


View more